Growth Hormone Stack (CJC-1295/Ipamorelin + IGF-1 LR3)
This Growth Hormone stack combines CJC-1295/Ipamorelin with IGF-1 LR3 for GH signaling, sleep support, and muscle growth research. The peptide names are in the title so this version is easy to distinguish from other “growth” stacks in the library.
Growth Hormone Stack Quick Overview
| Peptide | Purpose | Typical Dose |
|---|---|---|
| CJC-1295/Ipamorelin | GH release support | 200 mcg each nightly |
| IGF-1 LR3 | Anabolic and recovery signaling | 30–60 mcg daily |
What Is the Growth Hormone Stack
This stack combines a GH secretagogue pairing with an IGF-focused component. CJC-1295/Ipamorelin is often discussed for stimulating the body's own growth-hormone pulses, while IGF-1 LR3 is discussed more directly in muscle-recovery and growth signaling conversations.
Because there are multiple growth-oriented stacks in the planner, this page uses the exact peptide names in the title. That makes it clear this is the GH-plus-IGF version, not a different performance or bulking stack.
How the Stack Works
CJC-1295
- GHRH analog role — is commonly discussed for growth-hormone release support
- Longer stimulation pattern — is used to support GH signaling over time
- Sleep pairing — is frequently positioned around bedtime routines
Ipamorelin
- Selective secretagogue — is discussed for GH release with fewer off-target hormone effects
- Bedtime use — is commonly paired with fasted or pre-sleep administration
- Recovery interest — is often included for sleep and recovery support
IGF-1 LR3
- Downstream signaling — is discussed for muscle growth and repair pathways
- Post-workout use — is commonly positioned after training sessions
- Recovery amplification — may extend the stack beyond GH release alone
The stack pairs upstream GH signaling with downstream IGF-style recovery signaling. That is why it is often treated as a stronger growth-oriented option than secretagogues alone.
Benefits
- Growth-hormone release support
- Sleep and nighttime recovery positioning
- Muscle growth and post-training recovery support
- More explicit growth signaling than a secretagogue-only stack
- Clear differentiation from other growth-named stacks
Typical Protocol
| Week | CJC-1295/Ipamorelin | IGF-1 LR3 |
|---|---|---|
| 1–8 | 200 mcg each nightly | 30–60 mcg daily |
| 9–12 | Off or deload | Off or deload |
A common structure is 8 weeks on followed by 4 weeks off. For the secretagogue side of the stack, see the CJC-1295 results timeline and Ipamorelin results timeline.
Results Timeline
- Week 1–2: Sleep quality, recovery, and training readiness are early checkpoints
- Week 3–4: Users often look for improved recovery capacity and gym performance
- Week 5–8: Body-composition, muscle-growth, and recovery outcomes are the longer-range focus
Changes in body composition usually trail behind sleep and recovery changes. Use the component guides above for timing context rather than expecting uniform week-by-week results.
Stack Calculator
FAQs
What is the growth hormone stack?
This Growth Hormone stack combines CJC-1295/Ipamorelin with IGF-1 LR3. The page title uses the exact compounds so it is clearly differentiated from other similarly named growth or performance stacks.
Why combine CJC-1295/Ipamorelin with IGF-1 LR3?
CJC-1295/Ipamorelin is commonly discussed for GH-release support, while IGF-1 LR3 is discussed for downstream anabolic and recovery signaling. Together they are often framed as a growth-and-recovery pairing.
Is this the same as a bodybuilding stack?
Not exactly. It may overlap with performance-oriented goals, but this page frames the stack around growth-hormone signaling, sleep, recovery, and muscle-support research rather than a generic bodybuilding label.
How long does a growth hormone stack cycle last?
A common range is 8 weeks on followed by 4 weeks off, especially when IGF-1 LR3 is part of the protocol. Actual timing varies by component, tolerance, and research goal.
Is human evidence strong for this exact stack?
No. Human evidence for the full combination is limited. Most stack logic comes from separate GH secretagogue and IGF-related literature rather than direct trials on the exact protocol.
Sources
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (PubMed)
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (PubMed)
- Ipamorelin, the first selective growth hormone secretagogue (PubMed)
- Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption (PubMed)
- The therapeutic potential of IGF-I in skeletal muscle repair (PubMed)
Internal linking
Related Peptides
Related Protocols
Related Calculators
Related Stacks
For educational and research purposes only. Not medical advice. Consult a licensed healthcare professional for personal guidance.
